A new type of treatment, which could double the chances of survival for some patients suffering from the most common type of lung cancer, has been given Breakthrough Therapy Designation by the FDA.
Drug company Roche has been carrying out tests on an immunotherapy treatment, with early results suggesting it could be a better option than chemotherapy for those with non-small cell lung cancer. The research, which is to be presented at the annual meeting of the American Society of Clinical Oncology, has been welcomed by cancer charities.…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
